Brenig Therapeutics has launched an early Phase 1 clinical trial to evaluate its experimental small molecule BT-409 in healthy volunteers. The therapy is being developed for people with multiple sclerosis (MS) and other chronic neurologic conditions. It is aimed at blocking inflammatory responses by targeting the NLRP3 inflammasome, an immune complex that is abnormally activated in […]
The post Brenig launches Phase 1 trial of small molecule therapy for MS appeared first on Multiple Sclerosis News Today.
Source: multiplesclerosisnewstoday.com